Sign inJoin waitlistJoin the waitlist

MG

Mark Geyer

Chair, Quality Assessment, Cellular Therapy Service · New York Presbyterian Hospital

Credentials: · · · · · · · ·

History

Quality Assessment Department · New York Presbyterian Hospital
Present

Hematology and Medical Oncology
Memorial Sloan Kettering Cancer Center
2014–2017
Internal Medicine
Massachusetts General Hospital
2011–2014
Columbia Univ Coll of Phys & Surgeons
2007–2011

Research

IgH class switching and translocations use a robust non-classical end-joining pathway
Nature · 2007 · 477 citations
CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date
Blood · 2016 · 326 citations
Outcomes of COVID-19 in patients with CLL: a multicenter international experience
Blood · 2020 · 267 citations

JP
Jae Park
27 papers
MT
Martin Tallman
16 papers
Mitchell Cairo
15 papers
ES
Eytan Stein
14 papers
MR
Mikhail Roshal
12 papers
AG
Aaron Goldberg
11 papers
WX
Wenbin Xiao
11 papers · 2 as a fellow
Renier Brentjens
9 papers
Yanming Zhang
9 papers
JG
Jacob Glass
8 papers
AD
Ahmet Dogan
7 papers
KC
Kuo-Kai Chin
7 papers · 7 as a fellow

Grants

Development of Chimeric Antigen Receptor T Cells Targeting Cell Surface U5 snRNP for the Treatment of Acute Myeloid Leukemia
National Cancer Institute · R01
PI · $805.2K · Sloan-Kettering Inst Can Research
2025–2030
Iomab-ACT: A Phase I/II Study of 131-I Apamistamab Targeted Lymphodepletion Followed by CD19-Targeted CAR T-Cell Therapy for Patients with Relapsed or Refractory B-ALL or DLBCL
National Cancer Institute · R42
PI · $2.1M · Actinium Pharmaceuticals, Inc.
2020–2025

Clinical trials

A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
Principal investigator · Recruiting · Phase 1
Memorial Sloan Kettering Cancer Center
2023–2026
Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
Principal investigator · Recruiting · Early phase 1
Memorial Sloan Kettering Cancer Center
2021–2027
Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Principal investigator · Active not recruiting · Phase 2
Memorial Sloan Kettering Cancer Center
2020–2027